Literature DB >> 9308128

Hepatorenal syndrome.

R Bataller1, P Ginès, M Guevara, V Arroyo.   

Abstract

Hepatorenal syndrome is a common complication in patients with advanced cirrhosis and ascites characterized not only by renal failure but also by marked alterations in systemic hemodynamics and vasoactive systems. Renal failure is due to a marked hypoperfusion of the kidney secondary to renal vasoconstriction. The pathogenesis of hepatorenal syndrome is not completely known but it is thought to be the extreme manifestation of the underfilling of the arterial circulation secondary to an arterial vasodilation, located mainly in the splanchnic circulation. Recently, a new definition and diagnostic criteria of hepatorenal syndrome have been proposed, which has stimulated research in this field. Prognosis of patients with hepatorenal syndrome is very poor. Liver transplantation is the only effective treatment but it is not applicable in all patients due to short survival. New therapies developed during the last few years, such as the use of systemic vasoconstrictors or transjugular intrahepatic portosystemic shunts appear promising, but their usefulness should be evaluated in prospective investigations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308128     DOI: 10.1055/s-2007-1007201

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  12 in total

1.  Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis.

Authors:  Concepcíon Cassinello; Enrique Moreno; Adolfo Gozalo; Blanca Ortuño; Beatriz Cuenca; José Antonio Solís-Herruzo
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

2.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Authors:  K A Brensing; J Textor; J Perz; P Schiedermaier; P Raab; H Strunk; H U Klehr; H J Kramer; U Spengler; H Schild; T Sauerbruch
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

3.  Management of refractory ascites and hepatorenal syndrome.

Authors:  Amy N Sussman; Thomas D Boyer
Journal:  Curr Gastroenterol Rep       Date:  2011-02

4.  Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites.

Authors:  Mohammed Abdelhamid El-Bokl; Bahaa Eldeen Senousy; Khaled Zakaria El-Karmouty; Inas El Khedr Mohammed; Sherif Monier Mohammed; Sherif Sadek Shabana; Hassan Shalaby
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

Review 5.  Acute renal dysfunction in liver diseases.

Authors:  Alex-P Betrosian; Banwari Agarwal; Emmanuel E Douzinas
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

Review 6.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

7.  RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients.

Authors:  Chang-Chyi Jenq; Ming-Hung Tsai; Ya-Chung Tian; Chan-Yu Lin; Chun Yang; Nai-Jen Liu; Jau-Min Lien; Yung-Chang Chen; Ji-Tseng Fang; Pan-Chi Chen; Chih-Wei Yang
Journal:  Intensive Care Med       Date:  2007-06-30       Impact factor: 17.440

Review 8.  Albumin for end-stage liver disease.

Authors:  June Sung Lee
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

9.  Hepatorenal syndrome: outcome of response to therapy and predictors of survival.

Authors:  Jan Heidemann; Christoph Bartels; Christoph Berssenbrügge; Hartmut Schmidt; Tobias Meister
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

10.  Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.

Authors:  M Assem; M Elsabaawy; M Abdelrashed; S Elemam; S Khodeer; W Hamed; A Abdelaziz; G El-Azab
Journal:  Hepatol Int       Date:  2015-12-10       Impact factor: 9.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.